Thymosin Alpha-1 (Thymalfasin) Adverse Events: What Studies Report

Thymosin alpha-1 (Tα1; the pharmaceutical form is called thymalfasin) is a 28-amino-acid peptide derived from prothymosin alpha that has been studied as an immune modulator. A historical review of its use in infectious diseases traced its clinical investigation across viral hepatitis, sepsis and vaccine augmentation settings (PMID 26098768), and a 2023 review re-examined its applications in the immuno-oncology era alongside infectious-disease uses (PMID 36871535). This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medicine, a symptom or a treatment decision.

How adverse events appear in this literature

Readers looking for a frequency table of thymosin alpha-1 adverse events will find that the published base is organised around efficacy endpoints rather than systematic safety surveillance. The Cochrane review of thymic peptides in cancer patients was designed to assess both effectiveness and adverse effects of thymic peptides given alongside conventional treatment (PMID 21328265), which shows that reviewers have asked the safety question — but a stated review objective is not the same as a pooled incidence figure. Similarly, a systematic review and meta-analysis framed its comparison of entecavir plus thymosin alpha-1 against entecavir monotherapy in HBV-related cirrhosis explicitly around clinical efficacy and adverse effects (PMID 33076834).

Several of the most-cited thymosin alpha-1 papers are not human safety studies in any form. One laboratory report examined blood cells taken from patients with coronavirus disease 2019 and described effects of thymosin alpha-1 on cytokine-storm-related signalling in that ex vivo setting (PMID 33506065), a design that by definition cannot generate adverse-event data in people. Another study looked at lymphocyte immune homeostasis during post-acute sequelae of SARS-CoV-2 infection (PMID 36989892), reporting immunological measurements rather than a tolerability assessment.

Local and Injection-Site Effects: What Studies Report

Thymosin alpha-1 has been administered subcutaneously in the clinical settings covered by the historical infectious-disease review, which summarised the accumulated clinical experience with the peptide and characterised its tolerability in broad terms rather than as a graded adverse-event list (PMID 26098768). Reports of thymalfasin therapy in patients with chronic hepatitis B describe a subcutaneously injected course of treatment in that population (PMID 15546254), and a companion report in the same journal addressed the same indication (PMID 15641208). Where local reactions are discussed in this body of work, researchers generally mention them at the level of the injection route rather than quantifying rates by severity grade, and none of the verified sources on this page provides a per-patient incidence of injection-site reaction.

Constitutional and Systemic Effects: What Studies Report

Reviews covering the clinical use of thymosin alpha-1 across infectious disease have discussed tolerability as part of the case for further investigation (PMID 26098768), and the 2023 immuno-oncology review revisited the peptide's clinical profile across its studied indications (PMID 36871535). Narrative statements of that kind do not establish rates of fatigue, fever, myalgia, headache or other constitutional complaints, and the verified sources summarised here do not report such rates. A page that invented them would be reporting something no cited paper contains.

Hepatology Settings: What Studies Report

Chronic hepatitis B is the indication with the longest clinical track record for thymalfasin, and two 2004 reports in Journal of Gastroenterology and Hepatology describe thymalfasin therapy in patients with chronic hepatitis B (PMID 15546254; PMID 15641208). In cirrhotic patients, the systematic review and meta-analysis of entecavir plus thymosin alpha-1 versus entecavir monotherapy in HBV-related cirrhosis included adverse effects among its comparison outcomes (PMID 33076834), making it the single most directly relevant safety-oriented synthesis in this set. A Cochrane review comparing Phyllanthus species with antiviral drugs for chronic hepatitis B virus infection sits in the same comparative-evidence landscape, since antiviral and immunomodulatory comparators are the reference arms in that question (PMID 23633363).

A recurring theme in hepatitis B research is that immunomodulatory therapy is often compared against or combined with interferon-based or nucleos(t)ide-based regimens, so attributing a given symptom to thymosin alpha-1 rather than to the background regimen is not straightforward in combination trials such as those pooled in the entecavir comparison (PMID 33076834).

Oncology Settings: What Studies Report

The Cochrane review of thymic peptides for the treatment of cancer patients assessed thymic peptide preparations used alongside conventional cancer treatment, with effectiveness and adverse effects as the review questions (PMID 21328265). An earlier overview traced thymosin alpha-1 in cancer from basic research to clinical application, describing how the peptide moved from preclinical immunology into clinical investigation (PMID 11137613). The 2023 review in International Immunopharmacology reconsidered the peptide's broader applications in the immuno-oncology era (PMID 36871535). Where oncology trials administer thymosin alpha-1 with chemotherapy or other immunotherapy, the attribution problem is amplified: overlapping toxicity profiles mean that study-level adverse-event tables may not isolate the peptide's contribution, a limitation consistent with the mixed-intervention scope of the Cochrane review (PMID 21328265).

Immunological and Mechanistic Observations: What Studies Report

Because thymosin alpha-1 is studied as an immune modulator, several papers report immune-parameter changes rather than clinical adverse events. The study of post-acute sequelae of SARS-CoV-2 infection reported on lymphocyte immune homeostasis in that population (PMID 36989892), and the laboratory analysis of blood cells from COVID-19 patients examined cytokine-storm-related activity (PMID 33506065). A 2025 review in International Journal of Molecular Sciences placed thymosin alpha-1 in the context of ageing and immunosenescence (PMID 41373628). Changes in immune-cell populations are reported as study outcomes in these papers; they are not characterised there as harms, and none of these three sources frames its measurements as a safety endpoint.

Other Investigated Settings

Thymosin alpha-1 also appears in discussions of conditions where immune dysregulation is central. A 2018 article on unmet needs in cystic fibrosis discussed emerging biological approaches in that disease (PMID 30063865). Expert-opinion articles of this type describe rationale and research direction; they do not supply adverse-event incidence data, and the cystic fibrosis article is cited here for its scope rather than for any tolerability figure.

Source-by-Source Summary

What Is Not Established in These Sources

• No pooled incidence rates. None of the verified papers above provides a per-system adverse-event frequency table for thymosin alpha-1 that can be quoted without distortion, including the two systematic reviews that named adverse effects as an outcome (PMID 21328265; PMID 33076834).
• No long-term surveillance data. The ageing-focused review discussed the peptide in the context of immune decline rather than reporting multi-year follow-up safety outcomes (PMID 41373628).
• No isolated-agent toxicity profile in combination settings. Trials pooled in the HBV-related cirrhosis meta-analysis compared combination therapy against a monotherapy backbone (PMID 33076834).
• No extrapolation from laboratory work. The ex vivo COVID-19 blood-cell study reported cell-level findings only (PMID 33506065).

How to Read Tolerability Language in Reviews

Review articles frequently summarise an agent's clinical record with general descriptors, as the historical infectious-disease review did when surveying decades of use (PMID 26098768). Three cautions follow from that structure. First, narrative descriptors compress heterogeneous trials of differing size, duration and population. Second, trials designed around virological or oncological endpoints may collect adverse events less systematically than a dedicated safety study would, which is part of why the Cochrane reviewers specified adverse effects as a formal outcome in their protocol (PMID 21328265). Third, populations studied — people with chronic hepatitis B, cirrhosis, cancer or severe infection — differ from one another, so observations in one group do not transfer automatically to another, as the separate indication scopes of the hepatitis B reports and the oncology reviews illustrate (PMID 15546254; PMID 11137613).

Related Reading

For background on what thymosin alpha-1 is, how it has been studied and which indications dominate its literature, see the overview page: Thymosin Alpha-1.

References

• Historical review of thymosin α 1 in infectious diseases (Expert Opinion on Biological Therapy, 2015)
• Thymic peptides for treatment of cancer patients (Cochrane Database of Systematic Reviews, 2011)
• The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis (BMC Gastroenterology, 2020)
• Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B (Journal of Gastroenterology and Hepatology, 2004)
• Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B (Journal of Gastroenterology and Hepatology, 2004)
• Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era (International Immunopharmacology, 2023)
• Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application (International Journal of Immunopharmacology, 2000)
• Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection (International Immunopharmacology, 2023)
• Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients (Open Forum Infectious Diseases, 2021)
• Aging and Thymosin Alpha-1 (International Journal of Molecular Sciences, 2025)
• Unmet needs in cystic fibrosis (Expert Opinion on Biological Therapy, 2018)
• Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection (Cochrane Database of Systematic Reviews, 2013)